FilingIndex
8-KThe WireRoutine

Reg FD Disclosure

Filed Jun 18, 2025 · 1y ago · Accession 0001641172-25-015520

Plain English

Material event — a significant development the company must disclose promptly.

Read the source below for the full document.

Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended.   Item 9.01. Financial Statements and Exhibits.   (d) Exhibits.   Exhibit Number   Description       99.1   2025 Annual Meeting of Stockholders presentation slides 104   Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document).         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: June 18, 2025     PROVECTUS BIOPHARMACEUTICALS, INC.         By: /s/ Heather Raines     Heather Raines     Chief Financial Officer (Principal Financial Officer)
Filing details
Ticker
PVCT
CIK
315545
Form type
8-K
Filing date
Jun 18, 2025
Report date
Jun 18, 2025
Document
form8-k.htm
Size
4.2 MB